share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K:重大事件
美股SEC公告 ·  05/14 00:36

牛牛AI助理已提取核心訊息

On May 10, 2024, Avenue Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co. LLC, enabling the company to offer and sell shares of its common stock at its discretion. The shares will be sold pursuant to a shelf registration statement effective since December 10, 2021, with a prospectus supplement filed on the same date as the agreement. The company may sell up to $3,850,000 of its shares under this agreement, with H.C. Wainwright & Co. LLC acting as the sales agent. The sales agent will receive a 3.0% commission on gross proceeds and be reimbursed for certain expenses. Both parties have the right to terminate the agreement upon prior written notice, and the company is not obligated to sell any shares. The offering will conclude upon the sale of all shares or termination of the agreement. The details of the agreement were outlined in a Current Report on Form 8-K filed with the SEC, accompanied by legal opinions from Troutman Pepper Hamilton Sanders LLP.
On May 10, 2024, Avenue Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co. LLC, enabling the company to offer and sell shares of its common stock at its discretion. The shares will be sold pursuant to a shelf registration statement effective since December 10, 2021, with a prospectus supplement filed on the same date as the agreement. The company may sell up to $3,850,000 of its shares under this agreement, with H.C. Wainwright & Co. LLC acting as the sales agent. The sales agent will receive a 3.0% commission on gross proceeds and be reimbursed for certain expenses. Both parties have the right to terminate the agreement upon prior written notice, and the company is not obligated to sell any shares. The offering will conclude upon the sale of all shares or termination of the agreement. The details of the agreement were outlined in a Current Report on Form 8-K filed with the SEC, accompanied by legal opinions from Troutman Pepper Hamilton Sanders LLP.
2024年5月10日,Avenue Therapeutics, Inc.宣佈與H.C. Wainwright & Co.簽訂市場發行協議。有限責任公司,使公司能夠自行決定發行和出售其普通股。股票將根據自2021年12月10日起生效的上架註冊聲明出售,招股說明書補充文件將與協議同日提交。根據該協議,該公司可能與H.C. Wainwright & Co.出售高達385萬美元的股份。有限責任公司充當銷售代理。銷售代理將獲得總收益的3.0%的佣金,並報銷某些費用。雙方都有權在事先書面通知後終止協議,公司沒有義務出售任何股票。本次發行將在出售所有股份或終止協議時結束。向美國證券交易委員會提交的關於8-K表的最新報告概述了該協議的細節,並附有特勞特曼·佩珀·漢密爾頓·桑德斯律師事務所的法律意見。
2024年5月10日,Avenue Therapeutics, Inc.宣佈與H.C. Wainwright & Co.簽訂市場發行協議。有限責任公司,使公司能夠自行決定發行和出售其普通股。股票將根據自2021年12月10日起生效的上架註冊聲明出售,招股說明書補充文件將與協議同日提交。根據該協議,該公司可能與H.C. Wainwright & Co.出售高達385萬美元的股份。有限責任公司充當銷售代理。銷售代理將獲得總收益的3.0%的佣金,並報銷某些費用。雙方都有權在事先書面通知後終止協議,公司沒有義務出售任何股票。本次發行將在出售所有股份或終止協議時結束。向美國證券交易委員會提交的關於8-K表的最新報告概述了該協議的細節,並附有特勞特曼·佩珀·漢密爾頓·桑德斯律師事務所的法律意見。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。